1. PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

3. Goals

4. About Our Panel

5. 2013 ACC/AHA Cholesterol Guidelines Four Statin Benefit Groups Identified

6. IMPROVE-IT Simvastatin 40 mg vs Simvastatin/Ezetimibe 40 mg/10 mg

7. IMPROVE-IT (cont)

8. FOURIER: CV Outcomes

9. Clinical Implications of FOURIER

10. Statins Options

11. More Is Not Better

12. Multiple Challenges in Statin Selection

13. Statins: High/Medium/Low

14. Many Scenarios for Moderate Intensity

15. Recognize the At-Risk Populations

16. CYP450

17. Human Cytochrome P450 Isoenzymes Known to Oxidize Clinically Used Drugs

18. Selected Drug Interactions Increasing Statin Levels

19. Statins Not Metabolized by CYP450 System

20. Certain Statins Increase the Risk for New-Onset T2D

21. Statin Safety in HIV on ART Variable Increases in Statin AUC by Protease Inhibitors

22. Approach to Improve Adherence

23. Certain Statins Increase the Risk of New-Onset T2D (cont)

24. JUPITER: Rosuvastatin Therapy and Diabetes Risk

25. Use of Statins With Protease Inhibitors

26. Pitavastatin Does Not Adversely Affect FBG, HbA1c, or T2D Development

27. Diet and Exercise Approach to Reducing Risk for Diabetes

28. Patient-Centered Approach

29. Patient Education -- Team Approach

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)